175 related articles for article (PubMed ID: 32571185)
1. Immune Response and Protective Efficacy of Inactivated and Live Influenza Vaccines Against Homologous and Heterosubtypic Challenge.
Boravleva EY; Lunitsin AV; Kaplun AP; Bykova NV; Krasilnikov IV; Gambaryan AS
Biochemistry (Mosc); 2020 May; 85(5):553-566. PubMed ID: 32571185
[TBL] [Abstract][Full Text] [Related]
2. Comparative safety, immunogenicity, and efficacy of several anti-H5N1 influenza experimental vaccines in a mouse and chicken models (Testing of killed and live H5 vaccine).
Gambaryan AS; Lomakina NF; Boravleva EY; Kropotkina EA; Mashin VV; Krasilnikov IV; Klimov AI; Rudenko LG
Influenza Other Respir Viruses; 2012 May; 6(3):188-95. PubMed ID: 21951678
[TBL] [Abstract][Full Text] [Related]
3. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
4. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.
Budimir N; Huckriede A; Meijerhof T; Boon L; Gostick E; Price DA; Wilschut J; de Haan A
PLoS One; 2012; 7(1):e30898. PubMed ID: 22303469
[TBL] [Abstract][Full Text] [Related]
5. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
6. Characterization of cross protection of Swine-Origin Influenza Virus (S-OIV) H1N1 and reassortant H5N1 influenza vaccine in BALB/c mice given a single-dose vaccination.
Lin HT; Chuang CC; Wu HL; Chu DM; Wang YC
J Biomed Sci; 2013 Mar; 20(1):19. PubMed ID: 23517052
[TBL] [Abstract][Full Text] [Related]
7. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
[TBL] [Abstract][Full Text] [Related]
8. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
[TBL] [Abstract][Full Text] [Related]
9. [The immunogenic and protective properties of inactivated and live candidate vaccines against highly pathogenic avian influenza H5N1 virus].
Krasil'nikov IV; Gambarian AS; Mashin VV; Lobastova AK
Vopr Virusol; 2010; 55(4):16-9. PubMed ID: 20886707
[TBL] [Abstract][Full Text] [Related]
10. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.
Tumpey TM; Renshaw M; Clements JD; Katz JM
J Virol; 2001 Jun; 75(11):5141-50. PubMed ID: 11333895
[TBL] [Abstract][Full Text] [Related]
11. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.
Pedersen G; Major D; Roseby S; Wood J; Madhun AS; Cox RJ
Influenza Other Respir Viruses; 2011 Nov; 5(6):426-37. PubMed ID: 21668670
[TBL] [Abstract][Full Text] [Related]
12. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
13. Intranasal immunization of mice with inactivated virus and mast cell activator C48/80 elicits protective immunity against influenza H1 but not H5.
Xu L; Bao L; Li F; Lv Q; Yuan J; Xu Y; Deng W; Yao Y; Yu P; Qin C
Immunol Invest; 2014; 43(3):224-35. PubMed ID: 24295504
[TBL] [Abstract][Full Text] [Related]
14. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.
Zhao G; Sun S; Du L; Xiao W; Ru Z; Kou Z; Guo Y; Yu H; Jiang S; Lone Y; Zheng BJ; Zhou Y
Virol J; 2010 Jul; 7():151. PubMed ID: 20624292
[TBL] [Abstract][Full Text] [Related]
15. Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.
Bhide Y; Dong W; Gribonika I; Voshart D; Meijerhof T; de Vries-Idema J; Norley S; Guilfoyle K; Skeldon S; Engelhardt OG; Boon L; Christensen D; Lycke N; Huckriede A
Front Immunol; 2019; 10():646. PubMed ID: 30984200
[TBL] [Abstract][Full Text] [Related]
16. Protection against H5N1 highly pathogenic avian and pandemic (H1N1) 2009 influenza virus infection in cynomolgus monkeys by an inactivated H5N1 whole particle vaccine.
Nakayama M; Shichinohe S; Itoh Y; Ishigaki H; Kitano M; Arikata M; Pham VL; Ishida H; Kitagawa N; Okamatsu M; Sakoda Y; Ichikawa T; Tsuchiya H; Nakamura S; Le QM; Ito M; Kawaoka Y; Kida H; Ogasawara K
PLoS One; 2013; 8(12):e82740. PubMed ID: 24376571
[TBL] [Abstract][Full Text] [Related]
17. Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration.
Budimir N; de Haan A; Meijerhof T; Gostick E; Price DA; Huckriede A; Wilschut J
Influenza Other Respir Viruses; 2013 Nov; 7(6):1202-9. PubMed ID: 24102979
[TBL] [Abstract][Full Text] [Related]
18. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
[TBL] [Abstract][Full Text] [Related]
19. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.
Kistner O; Crowe BA; Wodal W; Kerschbaum A; Savidis-Dacho H; Sabarth N; Falkner FG; Mayerhofer I; Mundt W; Reiter M; Grillberger L; Tauer C; Graninger M; Sachslehner A; Schwendinger M; Brühl P; Kreil TR; Ehrlich HJ; Barrett PN
PLoS One; 2010 Feb; 5(2):e9349. PubMed ID: 20186321
[TBL] [Abstract][Full Text] [Related]
20. A prime-boost vaccination of mice with heterologous H5N1 strains.
Ikeno D; Kimachi K; Kudo Y; Goto S; Itamura S; Odagiri T; Tashiro M; Kino Y
Vaccine; 2009 May; 27(23):3121-5. PubMed ID: 19514127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
